Study Site 357 — Chattanooga, Tennessee

Study Site 357 is a clinical research site located in Chattanooga, Tennessee, United States.

Crixeo Clinical Trials Trust Score: 9/100 (FAILING). This profile has not yet been claimed by the site owner.

Study Site 357 has participated in 1 clinical trials.

Therapeutic areas: Pruritus, Atopic Dermatitis.

Sponsors: Vyne Therapeutics Inc..

Is this your site?

Is this your site? Claim your profile and control the information sponsors and patients see.

Other research sites in Chattanooga

Browse all research sites in Tennessee · View every site in Chattanooga

• University of Tennessee/Erlanger Oncology and Hematology
• University of Tennessee Erlanger Cardiology
• University Oncology/ Hematology Associates
• Center for Sports Medicine and Orthopaedics; Memorial Hospital
• Children's Hospital at Erlanger
• University of Tennessee-Chattanooga Unit
• University Oncology and Hematology Associates
• Memorial Hospital
• University of Diabetes and Endocrine Consultants
• University Diabetes & Endocrine Consultants /ID# 170392
• University of Tennessee Erlanger Oncology & Hematology
• Parkridge East Hospital

Sponsor Feasibility Report

Trust Score: 9/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for Study Site 357?

Study Site 357 has a Crixeo Trust Score of 9/100 (FAILING). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has Study Site 357 conducted?

Study Site 357 has 1 clinical trials on record. Their work covers Pruritus, Atopic Dermatitis.

Is Study Site 357 accredited by Crixeo Clinical Trials?

Study Site 357 has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about Study Site 357?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.